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Aims
(i) to identify outcomes of anti-epileptic drug (AED)
treatment patients consider important; (ii) to elicit
preferences for these outcomes and definitions of
equivalence; (iii) to investigate if perceptions of accepta-
ble trade-offs between benefits and harms differ across
different subgroups.
Methods
Web-based survey, containing discrete choice experiments
(DCEs) to elicit preferences of three pre-defined groups of
adults with epilepsy (n=750): (i) early epilepsy, (ii) estab-
lished epilepsy, (iii) women of childbearing age (WOCBA).
The DCEs contains five attributes, with two levels, defined
using: semi-structured interviews with patients (n=56), a
focus group with AED prescribers (n=8), and trial data.
Each used the same fractional factorial design, folded into
eight binary choices: Which medication would you prefer
to take? Target sample size is 750 respondents, recruited
via the Epilepsy Action website. Data will be analysed in
STATA using a random effects logit model.
Outcomes to date
Identified four common attributes: seizure-free, fewer
seizures, depression and memory problems. Fifth attri-
butes were feelings of aggression (early and established)
and foetal harm (WOCBA). The qualitative findings
suggest that preferences for negative outcomes vary by
sub-group. The results of the discrete choice experiment
will provide further information on acceptable trade-offs
between the benefits of remission and fewer seizures,
with potential harms; and thus indicate important out-
comes for clinical trials.
Conclusion
Exploring what people with epilepsy consider important
for measuring AED effectiveness will ensure clinical ser-
vices are focus on patient-defined needs and that future
research is designed to assess appropriate patient-
defined outcomes.
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